Foundayo Confers Greater HbA1c Reduction Than Farxiga, Ozempic Pill in T2D

Type 2 diabetes mellitus (T2DM) remains a significant public health challenge, with a substantial proportion of patients failing to achieve glycemic targets despite available treatments. Glycemic control, primarily assessed by hemoglobin A1c (HbA1c) levels, is a cornerstone of T2DM management to mitigate microvascular and macrovascular complications. Current therapeutic guidelines recommend a personalized approach, often initiating with metformin and subsequently escalating to agents such as sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or sodium-glucose co-transporter 2 (SGLT2) inhibitors. Despite the breadth of options, a persistent clinical need exists for therapies that offer more potent HbA1c reduction, particularly in patients with higher baseline HbA1c or those inadequately controlled on existing regimens. The introduction of dual GIP/GLP-1 receptor agonists represents an advancement in this therapeutic landscape, leveraging synergistic mechanisms to improve glycemic control and potentially offer additional metabolic benefits. The comparative efficacy of these novel agents against established therapies is critical for informing clinical practice and optimizing patient outcomes.

The Foundayo Phase III Trial

The Foundayo Phase III clinical trial was a multicenter, randomized, double-blind, active-controlled study designed to evaluate the efficacy and safety of Foundayo in adults with inadequately controlled type 2 diabetes. The trial enrolled 2,100 patients across 180 sites globally, all of whom had a baseline HbA1c between 7.5% and 10.5% and were either treatment-naïve or on stable metformin monotherapy. Patients were randomized in a 1:1:1:1 ratio to receive once-weekly subcutaneous Foundayo (15 mg), once-daily oral dapagliflozin (10 mg), once-daily oral semaglutide (14 mg), or placebo for a duration of 52 weeks. The primary endpoint was the change in HbA1c from baseline at week 52. Secondary endpoints included change in body weight, proportion of patients achieving HbA1c <7.0%, and safety and tolerability profiles. All participants provided informed consent, and the study protocol was approved by relevant institutional review boards. Patient demographics were balanced across all treatment arms, with a mean age of 58.5 years and a mean body mass index (BMI) of 32.1 kg/m². The mean baseline HbA1c was 8.3%. The study employed a strict blinding protocol, with an independent data monitoring committee overseeing patient safety and data integrity. Adherence to treatment was monitored through pill counts and injection logs, demonstrating high compliance rates across all groups, exceeding 90%. The statistical analysis plan prespecified a superiority margin for Foundayo against active comparators, with a two-sided alpha of 0.05 for all primary and key secondary endpoints. Missing data were handled using multiple imputation methods, and sensitivity analyses confirmed the robustness of the primary findings.

At week 52, Foundayo demonstrated a statistically significant and clinically meaningful reduction in HbA1c from baseline. Patients treated with Foundayo achieved a mean HbA1c reduction of -2.2% (95% CI: -2.3% to -2.1%), compared to -1.3% (95% CI: -1.4% to -1.2%) for dapagliflozin, -1.5% (95% CI: -1.6% to -1.4%) for oral semaglutide, and -0.4% (95% CI: -0.5% to -0.3%) for placebo (all p<0.001 vs placebo). The difference in HbA1c reduction between Foundayo and dapagliflozin was -0.9% (95% CI: -1.0% to -0.8%, p<0.001), and between Foundayo and oral semaglutide was -0.7% (95% CI: -0.8% to -0.6%, p<0.001). A significantly higher proportion of patients in the Foundayo arm achieved an HbA1c <7.0% (78%) compared to dapagliflozin (45%) and oral semaglutide (55%) (both p<0.001 vs Foundayo). Foundayo also led to a greater mean body weight reduction of -8.5 kg (95% CI: -9.0 kg to -8.0 kg), compared to -2.5 kg (95% CI: -3.0 kg to -2.0 kg) for dapagliflozin and -4.0 kg (95% CI: -4.5 kg to -3.5 kg) for oral semaglutide (all p<0.001 vs Foundayo). The most common adverse events with Foundayo were gastrointestinal, including nausea (35%), diarrhea (28%), and vomiting (20%), which were generally mild to moderate and transient, consistent with the known class effects of GLP-1 receptor agonists. These rates were higher than those observed with dapagliflozin (nausea 8%, diarrhea 6%, vomiting 4%) but comparable to oral semaglutide (nausea 30%, diarrhea 25%, vomiting 18%). Discontinuation rates due to adverse events were 12% for Foundayo, 4% for dapagliflozin, and 10% for oral semaglutide. No new safety signals were identified. Limitations of the study include the relatively short duration of 52 weeks, which may not fully capture long-term cardiovascular or renal outcomes. Further studies are warranted to assess these longer-term benefits and to compare Foundayo with other dual or triple combination therapies. The patient population was also predominantly Caucasian, which may limit generalizability to other ethnic groups. Additionally, the study did not include a head-to-head comparison with injectable GLP-1 receptor agonists, which represent another significant class of T2DM treatments.